Previous Close | 4.4000 |
Open | 4.0000 |
Bid | 4.3000 |
Ask | 4.5000 |
Strike | 14.00 |
Expire Date | 2024-06-21 |
Day's Range | 4.0000 - 4.4000 |
Contract Range | N/A |
Volume | |
Open Interest | 17 |
NEW YORK, May 09, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:
ATLANTA, May 09, 2024--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented new studies highlighting the significant impact of GAD in the US at ISPOR 2024, the leading global conference for health economics and outcomes research (HEOR) being held this week in Atlanta.
NEW YORK, May 08, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.